Abstract
Interleukin (IL)-8 is a chemokine that is essential for inflammation and angiogenesis. IL-8 expression is elevated in tumor cell lines and tissues, as well as in peripheral blood obtained from cancer patients. Primary works have attempted to determine the biological effect of IL-8 on tumor cells, including cell proliferation, survival, and migration. More recently, IL-8 has acquired considerable attention as an immune modulator in the context of certain tumor microenvironments (TME); specifically, it can support a niche that favors tumor progression and metastasis. Tumor-derived IL-8 stimulates inflammation by interacting with the microenvironmental constituents, including fibroblasts, endothelial cells, and immune cells. However, the tumor immune system is complex, and mechanisms that construct the immune phenotype remain incompletely characterized. Herein, we will (1) address a potential role of IL-8 in regulating gene expression to establish immune landscape in tumor. Then, we will (2) review IL-8 signaling in the maintenance of stem cells and regulation of hematopoietic progenitors. Finally, (3) IL-8 functions will be discussed in naturally occurring animal cancers that offer a clinically realistic model for translational research. This chapter will provide a new insight into the tumor immune niche and help us develop immunotherapies for cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14(6):e218–e228
Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741
Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, Teijeira A, Onate C, Gonzalez A, Ponz M, Schalper KA, Perez-Gracia JL, Melero I (2017) Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 60:24–31
Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56(5):559–564
Stillie R, Farooq SM, Gordon JR, Stadnyk AW (2009) The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 86(3):529–543
Wang N, Zhou R, Wang C, Guo X, Chen Z, Yang S, Li Y (2012) -251 T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep 39(3):2831–2841
Kim JH, Graef AJ, Dickerson EB, Modiano JF (2015) Pathobiology of hemangiosarcoma in dogs: research advances and future perspectives. Vet Sci 2(4):388–405
Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR (2001) Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod 7(8):787–790
Wang D, Richmond A (2001) Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 276(5):3650–3659
Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’Sullivan JM, Wilson RH, Johnston PG, Waugh DJ (2008) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327(3):746–759
MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ (2007) Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5(7):737–748
Pieper C, Pieloch P, Galla HJ (2013) Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res 1524:1–11
Smyth LCD, Rustenhoven J, Park TI, Schweder P, Jansson D, Heppner PA, O’Carroll SJ, Mee EW, Faull RLM, Curtis M et al (2018) Unique and shared inflammatory profiles of human brain endothelia and pericytes. J Neuroinflammation 15(1):138
Dar A, Domev H, Ben-Yosef O, Tzukerman M, Zeevi-Levin N, Novak A, Germanguz I, Amit M, Itskovitz-Eldor J (2012) Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 125(1):87–99
Stratman AN, Schwindt AE, Malotte KM, Davis GE (2010) Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 116(22):4720–4730
Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307(1):C25–C38
Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O (2013) Type-1 pericytes participate in fibrous tissue deposition in aged skeletal muscle. Am J Physiol Cell Physiol 305(11):C1098–C1113
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457
Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA et al (2018) The immune landscape of cancer. Immunity 48(4):812–830.e814
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938–945
Wefers C, Schreibelt G, Massuger L, de Vries IJM, Torensma R (2018) Immune curbing of cancer stem cells by CTLs directed to NANOG. Front Immunol 9:1412
Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485–497
Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB et al (2012) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55(3):807–820
Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH et al (2011) SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 141(1):279–291, 291 e271–275
Sannino G, Marchetto A, Kirchner T, Grunewald TGP (2017) Epithelial-to-mesenchymal and mesenchymal-to-epithelial transition in mesenchymal tumors: a paradox in sarcomas? Cancer Res 77(17):4556–4561
Li Y, Laterra J (2012) Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 72(3):576–580
Zhou H, Neelakantan D, Ford HL (2017) Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol 64:79–89
Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H (2010) SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 10:411
Savagner P, Karavanova I, Perantoni A, Thiery JP, Yamada KM (1998) Slug mRNA is expressed by specific mesodermal derivatives during rodent organogenesis. Dev Dyn 213(2):182–187
Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, Sanchez ML, Orfao A, Flores T, Sanchez-Garcia I (2002) Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood 100(4):1274–1286
Wu Y, Zhou BP (2010) Snail: more than EMT. Cell Adhes Migr 4(2):199–203
Perez-Mancera PA, Gonzalez-Herrero I, Perez-Caro M, Gutierrez-Cianca N, Flores T, Gutierrez-Adan A, Pintado B, Sanchez-Martin M, Sanchez-Garcia I (2005) SLUG in cancer development. Oncogene 24(19):3073–3082
Lilly AJ, Johnson WE, Bunce CM (2011) The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour. Stem Cells Int 2011:274564
Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382(6592):635–638
Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393(6685):595–599
Li KC, Huang YH, Ho CY, Chu CY, Cha ST, Tsai HH, Ko JY, Chang CC, Tan CT (2012) The role of IL-8 in the SDF-1alpha/CXCR4-induced angiogenesis of laryngeal and hypopharyngeal squamous cell carcinoma. Oral Oncol 48(6):507–515
Mendt M, Cardier JE (2015) Role of SDF-1 (CXCL12) in regulating hematopoietic stem and progenitor cells traffic into the liver during extramedullary hematopoiesis induced by G-CSF, AMD3100 and PHZ. Cytokine 76(2):214–221
Jung JH, Lee SJ, Kim J, Lee S, Sung HJ, An J, Park Y, Kim BS (2015) CXCR2 and its related ligands play a novel role in supporting the pluripotency and proliferation of human pluripotent stem cells. Stem Cells Dev 24(8):948–961
Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, Ema H, Nakauchi H (2013) Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 154(5):1112–1126
Ito K, Bonora M, Ito K (2019) Metabolism as master of hematopoietic stem cell fate. Int J Hematol 109(1):18–27
Kondo M, Scherer DC, Miyamoto T, King AG, Akashi K, Sugamura K, Weissman IL (2000) Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature 407(6802):383–386
Rieger MA, Hoppe PS, Smejkal BM, Eitelhuber AC, Schroeder T (2009) Hematopoietic cytokines can instruct lineage choice. Science 325(5937):217–218
Sarrazin S, Mossadegh-Keller N, Fukao T, Aziz A, Mourcin F, Vanhille L, Kelly Modis L, Kastner P, Chan S, Duprez E et al (2009) MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell 138(2):300–313
Blogowski W, Deskur A, Budkowska M, Salata D, Madej-Michniewicz A, Dabkowski K, Dolegowska B, Starzynska T (2014) Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS One 9(5):e97613
Sendo S, Saegusa J, Morinobu A (2018) Myeloid-derived suppressor cells in non-neoplastic inflamed organs. Inflamm Regen 38:19
Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A et al (2016) Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res 22(15):3924–3936
Gonzalez-Aparicio M, Alfaro C (2019) Influence of interleukin-8 and neutrophil extracellular trap (NET) formation in the tumor microenvironment: is there a pathogenic role? J Immunol Res 2019:6252138
Alfaro C, Suarez N, Martinez-Forero I, Palazon A, Rouzaut A, Solano S, Feijoo E, Gurpide A, Bolanos E, Erro L et al (2011) Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One 6(3):e17922
Dowling MF (2018) Understanding the role of interleukin-8 (IL-8) in canine osteosarcoma metastasis. University of Illinois at Urbana-Champaign. http://hdl.handle.net/2142/101656
Casadevall A, Pirofski LA (2014) Microbiology: ditch the term pathogen. Nature 516(7530):165–166
Tomasetti C, Vogelstein B (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347(6217):78–81
Tomasetti C, Li L, Vogelstein B (2017) Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355(6331):1330–1334
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998
Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360
Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol 27:16–25
Overgaard NH, Fan TM, Schachtschneider KM, Principe DR, Schook LB, Jungersen G (2018) Of mice, dogs, pigs, and men: choosing the appropriate model for immuno-oncology research. ILAR J 59:247
Kim JH, Yu CH, Yhee JY, Im KS, Sur JH (2010) Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. J Comp Pathol 142(2–3):177–186
Kim JH, Chon SK, Im KS, Kim NH, Cho KW, Sur JH (2013) Infiltrating Foxp3+ regulatory T cells and histopathological features in canine classical and spermatocytic seminomas. Reprod Domest Anim 48(2):218–222
Kim JH, Hur JH, Lee SM, Im KS, Kim NH, Sur JH (2012) Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas. Vet J 193(1):222–227
Porcellato I, Brachelente C, De Paolis L, Menchetti L, Silvestri S, Sforna M, Vichi G, Iussich S, Mechelli L (2019) FoxP3 and IDO in canine melanocytic tumors. Vet Pathol 56(2):189–199
Filley A, Henriquez M, Bhowmik T, Tewari BN, Rao X, Wan J, Miller MA, Liu Y, Bentley RT, Dey M (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neuro-Oncol 137(3):469–479
Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC et al (2012) Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther 20(12):2234–2243
Estrela-Lima A, Araujo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 10:256
Davoli T, Uno H, Wooten EC, Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355(6322):eaaf8399
Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I et al (2015) PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160(4):700–714
Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O’Brien TD, Spector LG et al (2018) Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res 78(2):326–337
Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O’Sullivan MG, Subramanian S, Bryan BA, Modiano JF (2016) Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech 9(12):1435–1444
Kim JH, Megquier K, Sarver AL, Thomas R, Wang C, Elvers I, Karlsson E, Breen M, Lindblad-Toh K, Modiano JF (2018) Mutational and transcriptomic profiling identify distinct angiogenic and inflammatory subtypes of angiosarcoma. In: AACR annual meeting. American Association for Cancer Research, Chicago, p 2018
Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM et al (2004) Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Investig 84(5):562–572
Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR et al (2010) Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 10:619
Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF (2009) Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 4(5):e5549
Kim JH, Frantz AM, Anderson KL, Graef AJ, Scott MC, Robinson S, Sharkey LC, O’Brien TD, Dickerson EB, Modiano JF (2014) Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Exp Cell Res 323(1):155–164
Rovai LE, Herschman HR, Smith JB (1998) The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukoc Biol 64(4):494–502
Asfaha S, Dubeykovskiy AN, Tomita H, Yang X, Stokes S, Shibata W, Friedman RA, Ariyama H, Dubeykovskaya ZA, Muthupalani S et al (2013) Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 144(1):155–166
Moldobaeva A, Baek A, Eldridge L, Wagner EM (2010) Differential activity of pro-angiogenic CXC chemokines. Microvasc Res 80(1):18–22
Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, Helfand SC (2004) Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 6(2):106–116
Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA et al (2013) Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Mol Cancer Ther 12(9):1701–1714
Murai A, Asa SA, Kodama A, Hirata A, Yanai T, Sakai H (2012) Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res 8:128
Kodama A, Sakai H, Matsuura S, Murakami M, Murai A, Mori T, Maruo K, Kimura T, Masegi T, Yanai T (2009) Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer 9:363
Kim JH, Frantz AM, Sarver AL, Gorden Klukas BH, Lewellen M, O’Brien TD, Dickerson EB, Modiano JF (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16(1):E176–E184
Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL et al (2017) Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Mol Cancer Ther 16(5):956–965
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kim, JH. (2020). Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1240. Springer, Cham. https://doi.org/10.1007/978-3-030-38315-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-38315-2_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-38314-5
Online ISBN: 978-3-030-38315-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)